The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets

European Journal of Pharmacology

Volumn 747, Issue , 2015, Pages 160-165

  Uchida, Shin Ichi ^a   Soshiroda, Kazuhiro ^a   Okita, Eri ^a   Kawai Uchida, Mika ^a   Mori, Akihisa ^a   Jenner, Peter ^b   Kanda, Tomoyuki ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adenosine A2A receptorantagonist; Anti parkinsonian; Dopamine agonist; MPTP

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ISTRADEFYLLINE; PERGOLIDE; ROPINIROLE; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; INDOLE DERIVATIVE; LEVODOPA; PURINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPARKINSON ACTIVITY; ARTICLE; CALLITHRIX; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; LOCOMOTION; LOW DRUG DOSE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MPTP-INDUCED PARKINSONISM; NONHUMAN; OUTCOME ASSESSMENT; RECEPTOR BLOCKING; ANIMAL; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MOTOR ACTIVITY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; CALLITHRIX; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; INDOLES; LEVODOPA; MALE; MOTOR ACTIVITY; PERGOLIDE; PURINES; RECEPTOR, ADENOSINE A2A;

EID: 84919819743     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.11.038     Document Type: Article

References (19)

1. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Movement Disord. 16 2001 448 458
2. M. DeLong Primate models of movement disorders of basal ganglia origin Trends Neurosci. 13 1990 281 285
3. S. Fahn The history of dopamine and levodopa in the treatment of Parkinson's disease Movement Disord. 23 2008 S497 S508
4. G.J. Fici, H. Wu, P.F. VonVoigtlander, and V.H. Sethy D1 dopamine receptor activity of anti-parkinsonian drugs Life Sci. 60 1997 1597 1603
5. R.A. Hauser, L.M. Shulman, J.M. Trugman, J.W. Roberts, A. Mori, R. Ballerini, and N.M. Sussman Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations Movement Disord. 23 2008 2177 2185
6. 2A antagonists, and Parkinson's disease Parkinsonism Relat. D. 15 2009 406 413
7. 2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys Exp. Neurol. 162 2000 321 327
8. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann. Neurol. 43 1998 507 513
9. 2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-parkinsonian rats Eur. J. Pharmacol. 408 2000 249 255
10. 2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005) Ann. Neurol. 63 2008 295 302
11. S.Z. Marsala, M. Gioulis, R. Ceravolo, and M. Tinazzi A systematic review of catechol-o-methyltransferase inhibitors: efficacy and safety in clinical practice Clin. Neuropharmacol. 35 2012 185 190
12. 2A receptor antagonist istradefylline reduces daily off time in Parkinson's disease Movement Disord. 28 2013 1138 1141
13. 2A antagonists Neurology 61 2003 S44 S48
14. J.G. Nutt Motor fluctuations and dyskinesia in Parkinson's disease Parkinsonism Relat. D. 8 2001 101 108
15. S. Perez-Lloret, and O. Rascol Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease CNS Drugs 24 2010 941 968
16. M. Raja, and A.R. Bentivoglio Impulsive and compulsive behaviors during dopamine replacement treatment in Parkinson's disease and other disorders Curr. Drug Safe. 7 2012 63 75
17. A.H. Schapira Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects CNS Drugs 25 2011 1061 1071
18. L.A. Smith, A. Gordin, P. Jenner, and C.D. Marsden Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets Movement Disord. 12 1997 935 945
19. 2A receptor antagonist, istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets J. Pharmacol. Sci. 124 2014 480 485